Tudor Investment Corp ET AL Takes $15.13 Million Position in Revvity Inc. $RVTY

Tudor Investment Corp ET AL purchased a new stake in Revvity Inc. (NYSE:RVTY) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 172,601 shares of the company’s stock, valued at approximately $15,128,000.

A number of other hedge funds have also bought and sold shares of the business. CYBER HORNET ETFs LLC bought a new stake in Revvity in the 2nd quarter valued at about $32,000. MUFG Securities EMEA plc acquired a new position in shares of Revvity during the 2nd quarter worth approximately $34,000. Headlands Technologies LLC bought a new position in shares of Revvity during the second quarter worth approximately $49,000. Smartleaf Asset Management LLC increased its holdings in shares of Revvity by 56.8% during the third quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock worth $58,000 after purchasing an additional 250 shares during the period. Finally, Quent Capital LLC acquired a new stake in shares of Revvity in the third quarter valued at approximately $71,000. 86.65% of the stock is owned by institutional investors.

Revvity Stock Up 0.2%

Shares of RVTY opened at $89.12 on Friday. Revvity Inc. has a one year low of $81.36 and a one year high of $118.30. The company has a market cap of $9.96 billion, a P/E ratio of 42.85, a P/E/G ratio of 1.89 and a beta of 1.13. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $95.43 and a two-hundred day simple moving average of $96.60.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $772.06 million for the quarter, compared to the consensus estimate of $759.81 million. During the same quarter last year, the business posted $1.42 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Research analysts forecast that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s dividend payout ratio (DPR) is 13.46%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RVTY shares. Jefferies Financial Group boosted their price target on Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Wells Fargo & Company lifted their price objective on Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. TD Cowen reiterated a “hold” rating on shares of Revvity in a research report on Tuesday, February 3rd. Barclays increased their target price on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Finally, Wall Street Zen upgraded Revvity from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $112.92.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.